Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I
- PMID: 15102877
- DOI: 10.1194/jlr.R400003-JLR200
Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I
Abstract
This is the first of a series of reviews of the controversy that swirled around the "lipid hypothesis" of atherosclerosis for so many years. Today, in the era of the statins, there is no longer any doubt about the value of decreasing blood cholesterol levels. In fact, "the lower the better" is the position of many clinicians. However, getting to this point has been a long uphill battle marked by heated debate and sometimes violent disagreement. The history of this controversy is worth telling for its own sake and because remembering it may help us avoid similar mistakes in the future. The history of this controversy is worth telling for its own sake and because remembering it may help us avoid similar mistakes in the future.
Copyright 2004 American Society for Biochemistry and Molecular Biology, Inc.
Comment in
-
Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy.J Lipid Res. 2006 Jul;47(7):1339-51. doi: 10.1194/jlr.R600009-JLR200. Epub 2006 Apr 3. J Lipid Res. 2006. PMID: 16585781 Review.
Similar articles
-
Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia.J Lipid Res. 2005 Oct;46(10):2037-51. doi: 10.1194/jlr.R500010-JLR200. Epub 2005 Jul 1. J Lipid Res. 2005. PMID: 15995167
-
Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy.J Lipid Res. 2006 Jul;47(7):1339-51. doi: 10.1194/jlr.R600009-JLR200. Epub 2006 Apr 3. J Lipid Res. 2006. PMID: 16585781 Review.
-
The cholesterol controversy continues.MLO Med Lab Obs. 2008 Apr;40(4):24, 26, 28 passim. MLO Med Lab Obs. 2008. PMID: 18488541 No abstract available.
-
Intermediate lipoproteins, atherosclerosis, and Gofman.Circulation. 1998 Feb 24;97(7):708. Circulation. 1998. PMID: 9495311 No abstract available.
-
The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr. Yoshio Watanabe.Atherosclerosis. 2009 Nov;207(1):1-7. doi: 10.1016/j.atherosclerosis.2009.03.024. Epub 2009 Apr 1. Atherosclerosis. 2009. PMID: 19389675 Review.
Cited by
-
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9.J Lipid Res. 2011 Apr;52(4):679-87. doi: 10.1194/jlr.M013664. Epub 2011 Jan 24. J Lipid Res. 2011. PMID: 21262787 Free PMC article.
-
Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies.Diseases. 2018 Mar 17;6(1):22. doi: 10.3390/diseases6010022. Diseases. 2018. PMID: 29562587 Free PMC article. Review.
-
Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine.Pharmacol Ther. 2015 Feb;146:104-19. doi: 10.1016/j.pharmthera.2014.09.009. Epub 2014 Sep 30. Pharmacol Ther. 2015. PMID: 25277507 Free PMC article. Review.
-
Genetically Modified Rabbits for Cardiovascular Research.Front Genet. 2021 Feb 2;12:614379. doi: 10.3389/fgene.2021.614379. eCollection 2021. Front Genet. 2021. PMID: 33603774 Free PMC article. Review.
-
The early years of lipoprotein research: from discovery to clinical application.J Lipid Res. 2016 Oct;57(10):1771-1777. doi: 10.1194/jlr.R069575. Epub 2016 Jul 29. J Lipid Res. 2016. PMID: 27474223 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical